Novel agents and autologous transplants have substantially improved the treatment and quality of life of patients with multiple myeloma; however, myeloma remains an incurable disease plagued by multiple relapses and increasing resistance to therapy [1] . When patients relapse or the disease progresses after an upfront single or tandem transplantation, salvage treatment options are still limited. Treatment options include salvage chemotherapy, salvage autologous stem cell transplants (ASCT), and allogeneic hematopoietic stem cell transplantation. Unfortunately, there is no clear recommendation regarding choice of salvage therapy for relapsed/refractory multiple myeloma (RRMM) [2, 3] . Allogeneic stem cell transplantation (allo SCT) is a wellestablished immunotherapy strategy for multiple myeloma with evidence of the existence of a potent and often sustained graft-versus-myeloma effect. During the early use of the procedure, the treatment-related mortality (TRM) following allo SCT for multiple myeloma ranged from 40 to 60% [4] [5] [6] . Since then, the TRM after myeloablative and reduced intensity conditioned allogeneic hematopoietic stem cell transplantation (HCT) has decreased over time (48% TRM between 1995-2000 vs. 29% TRM between  2001 and 2005) with further improvements expected due to improvements in supportive care and new preparative regimens [7] . Recently, the development of alternative haploidentical related donors has resulted in high-risk hematologic malignancies that could be tolerable and curable. Among these novel approaches, the Beijing protocol has been successfully used in the treatment of a variety of hematologic diseases. To date, little is known on the use of haploidentical SCT in patients with multiple myeloma [8] . As mentioned above, despite newer myeloma agents and combinations of cytotoxic agents, multiple myeloma eventually has a chemotherapy resistant, refractory recurrence. Previously, we reported on the safety and efficacy of using matched sibling donors as a therapy for multiple myeloma [9] . Based on prior research, haploidentical donors might be a useful source for RRMM as it is difficult to find a suitable sibling donor. Therefore, we retrospectively investigated the database of haploidentical SCT for RRMM in our institute.
Between December 2004 and December 2015, nine patients from Peking University People's Hospital were enrolled in the current analysis. Patients older than 18 years and younger than 60 years with RRMM according to the International Myeloma Working Group criteria [2] were eligible for inclusion. The patients were unable to undergo salvage autologous transplantation and were eligible for haploidentical allo SCT without matched sibling donors or unrelated donors. Preconditioning consisted of cytarabine (4 g/m2/day, −10 to −9 days), busulfan (3.2 mg/kg/day, days −8 to −6), cyclophosphamide (1.8 g/m2/day, days −5 to −4), and simustine (250 mg/m2, day −3) along with rabbit anti-thymocyte globulin (ATG) (2.5 mg/kg, days −5 to −2). Prophylaxis for GVHD was the same for all patients. Recipients received CsA, mycophenolate mofetil, and short-term MTX. All nine patients had RRMM. Two patients developed disease recurrence after one or two prior autologous transplants, whereas the other seven patients did not have a prior autologous transplant due to failure to collect autologous stem cell grafts. At the time of haploidentical SCT, five patients had responded to prior therapy, whereas four patients did not achieve at least a PR. Among four patients with cytogenetic assays available at diagnosis, one had 17p deletion plus complex karyotype, one had 1q21 /L was reached at a median of 13 days after transplantation (range, 10-23 days) and the median time to reach a stable platelet count > 20 × 10 9 /L was 28 days (range, 13-50 days). Two patients with previous ASCT did not achieve platelet reconstitution. The median percentage of donor cells at day 30 posttransplantation was 100%. No patient developed grade 3-4 aGVHD. Grade 1-2 aGVHD occurred in seven patients (77.8%) and extensive cGVHD in three patients (42.9%). The two patients that received previous ASCT died early, at around 2 months post-transplantation. All the patients reached CR and PR, respectively, on day +100 after transplant. CR and PR in patients who survived at least 3 months after transplant were 71.4% and 28.6%, respectively, for an overall response rate of 100%. More details were given in Table 2 . Three patients (33.3%) subsequently relapsed, one of them with extramedullary involvement. Relapse was day +180, day +365 and day +623 after transplant, respectively. The cumulative incidence of relapse was 57.1% at 2 years.
After a median follow-up of 303 days, four patients died, two due to relapse and two that received previous ASCT due to NRM within 100 days posttransplant. Causes of NRM were CMV pneumonia in one patient and sepsis related multi-organ failure in the other. The cumulative incidence of NRM, OS, and PFS at 2 years was 22.2, 66.7, and 33.3%, respectively.
Despite newer myeloma agents (immunomodulatory agents and proteasome inhibitors), and combination of cytotoxic agents, PFS in the majority of patients with RRMM is only 3.7-14 months [10] . These numbers highlight the need for more effective therapy, especially in younger patients with good performance status. Some investigators have reported the use of allogeneic transplantation as a salvage approach for patients failing prior therapies. In this study, we evaluated the feasibility of haploidentical grafts as an alternative graft source for RRMM. All the patients achieved full donor chimerism with comparable recovery to those after haploidentical grafts for other hematological malignancies in our institute. The cumulative incidence of NRM at year 2 was 22.2%. The Center for International Blood and Marrow Transplant Research registry 1-year NRM for reduced intensity Data presented are n (%), unless indicated otherwise. conditioning (RIC) was 13% [11] . An European Society for Blood and Marrow Transplantation (EBMT) analysis of a large number of patients who underwent RIC, most of them after autotransplant failure, reported an NRM of 22% [12] . Various single institutions reported that NRM varied from 11 to 26%. Recently, EBMT reported that the NRM for salvage transplantation using unrelated donors at 2 years was 22% [13] . These current results are encouraging considering that all the enrolled patients in this study underwent myeloablative conditioning regimen as salvage allo SCT. The combination of busulfan with cyclophosphamide has been used for decades as an alternative preparative regimen in multiple myeloma before ASCT. We continued to use the Beijing Protocol, including these two drugs for preconditioning, as we previously reported in a study of matched sibling donors for multiple myeloma [8] . The incidence of grade II to IV aGVHD was comparable with that observed in other patient cohorts, presumably because of ATG use, intensified suppression, and the use of allografts BM combined with PBSC in our study population. Similarly, Kröger et al. [14] reported that ATG as part of the conditioning regimen resulted in a low incidence of severe GVHD in patients with advanced multiple myeloma.
The major obstacle associated with the enrolled patients is the high incidence of relapse (57.1%). Several factors are likely contributory. Clearly, the enrolled patients were at extremely high risk for primary disease. Eight (88.9%) had residual disease at the time of transplant. Disease status is still an important factor affecting prognosis. Second, the optimal dose of ATG is still uncertain in haploidentical SCT. The dose of ATG (10 mg/kg) was the same as generally used for leukemia patients and post-SCT exposure may have depleted most T cells accompanying the grafts, leading to delayed T-cell reconstitution. ATG dose deescalation could be explored in follow-up research to allow faster lymphocyte reconstitution. Third, maintenance post allo SCT is still unresolved. Like in autologous transplantation, a maintenance strategy with novel agents alone or in combination with donor lymphocyte infusion should be investigated after salvage allogeneic transplantation to reduce the risk of relapse.
In conclusion, allo SCT continues to be offered to a significant portion of patients with RRMM and suitable donors can be identified. The current data showed that haploidentical SCT was feasible for RRMM. Importantly, all the enrolled patients achieved full donor chimerism and comparable incidence of aGVHD. Despite small numbers and limited follow-up, the current analysis suggested that haploidentical grafts may provide therapy choice and improve patient outcomes. The key area of interest for future allo SCT trials in multiple myeloma would be relapse risk reduction by incorporation of newer drugs or cytotherapy into maintenance therapy posttransplant.
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